Research has found that stimulating the STING pathway, and inhibiting epigenetic modifiers that silence the STING pathway, has shown success in inhibiting tumor growth in patients that have not been responsive to previous types of immunotherapy [45]. The gene discussed is STING1; the disease is neoplasm.